Product nameAnti-DR4 antibody [DR-4-02] - Low endotoxin, Azide free
See all DR4 primary antibodies
DescriptionMouse monoclonal [DR-4-02] to DR4 - Low endotoxin, Azide free
Tested applicationsSuitable for: IP, Functional Studies, Flow Cyt, ICC/IFmore details
Species reactivityReacts with: Human
Fusion protein (Human). Fusion protein containing the extracellular part of DR4 and the constant part of the heavy chain of the human IgG1.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.
Storage bufferPreservative: None
Constituents: PBS, pH 7.4
Concentration information loading...
PurityProtein A purified
Our Abpromise guarantee covers the use of ab14738 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
FuncS: Use at an assay dependent dilution.Soluble antibody blocks DR4 receptor against TRAIL-induced apoptosis. Plastic-immobilized antibody induces apoptosis in sensitive cells.
Recommended dilution of antibody: 2-3 µg/ml in cultivation medium
Final concentration of TRAIL: 20-200 ng/ml
Application note: It is recommended to add the antibody 15 min before addition of TRAIL.
ICC/IF: Use at an assay dependent dilution.
IP: Use at an assay dependent dilution.
Not tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
FunctionReceptor for the cytotoxic ligand TNFSF10/TRAIL. The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. Promotes the activation of NF-kappa-B.
Tissue specificityWidely expressed. High levels are found in spleen, peripheral blood leukocytes, small intestine and thymus, but also in K562 erythroleukemia cells, MCF7 breast carcinoma cells and activated T-cells.
Sequence similaritiesContains 1 death domain.
Contains 3 TNFR-Cys repeats.
- Information by UniProt
- Apo2 antibody
- CD261 antibody
- Cytotoxic TRAIL receptor antibody
Flow Cytometry analysis of DR4 expression on the surface of hematopoietic cell lines. Cells were stained with purified anti-DR4 antibodies (ab14738) followed by Goat anti-mouse IgG PE. Histograms: Red - Goat anti-mouse IgG PE (no primary antibody) Black - anti-DR4 comparative antibody Blue and Green - anti-DR4 (ab14738:DR-4-02) in duplicate staining
Immunofluorescence staining (confocal microscopy) of HeLa human cervix carcinoma cell line transfected with DR4 expression plasmid using anti-human DR4 (ab14738:DR-4-02).
This product has been referenced in:
- Passante E et al. Systems analysis of apoptosis protein expression allows the case-specific prediction of cell death responsiveness of melanoma cells. Cell Death Differ 20:1521-31 (2013). Read more (PubMed: 23933815) »
- Franzen CA et al. Matrix protein CCN1 is critical for prostate carcinoma cell proliferation and TRAIL-induced apoptosis. Mol Cancer Res 7:1045-55 (2009). Read more (PubMed: 19584265) »